ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Toll-Like Receptor 4 Blockade Enhances Islet Engraftment and Induces Indefinite Islet Allograft Survival

T. Berney, L. Giovannoni, V. Lavallard, Y. Muller, S. Lacotte, P. Morel, C. Toso, L. Shang, B. Daubeuf, M. Kosco-Vilbois, D. Bosco

Department of Surgery, University Hospitals of Geneva, Geneva, Switzerland
NovImmune, Geneva, Switzerland

Meeting: 2013 American Transplant Congress

Abstract number: A671

Related Abstracts
  • Knockdown of Intra-Islet IKKβ by Spherical Nucleic Acid Nanoparticle Conjugates Prevents Host Cytokine-Induced Injury and Enhances Islet Graft Survival
  • Improving Pancreatic Islet Engraftment through Manipulation of Their Size

The aim of the present study was to assess the role of Toll-like-receptor 4 (TLR4) in mediating the immune response to allogeneic pancreatic islets.

We first assessed the impact of TLR4 blockade on human Β-cell apoptosis using anti-TLR4 monoclonal antibody (mAb). Human or mouse islets were then co-cultured with allogeneic lymphocytes ± anti-TLR4 mAbs. T-cell proliferation and IFNΓ secretion were assessed. In vivo, we used both a syngeneic (B6-to-B6)marginal mass islet transplant model and an allogeneic (DBA1-to-B6) model. Islets and/or recipients were treated with anti-TLR4 mAb. Islets were transplanted under the kidney capsule of chemically diabetic mice.

TLR4 blockade in vitro inhibited LPS-mediated human Β-cell apoptosis (p=0.014), T-cell proliferation against human (79±2% p<0.0001) and murine (67±16% p=0.004) islets, and IFNΓ-secreting-cell number (human: 62±9% (p=0.0049); mouse: 64±10% (p<0.0001)). In vivo, marginal mass syngeneic islet transplantation resulted in 100% recipients reversing diabetes in a median time of 7 days, as compared to 75% in 20.5 days in controls, indicating better engraftment in the absence of immune phenomena. Anti-TLR4 treatment of both islets and recipients led to indefinite graft survival (>100 days) in 63% of animals (p=0.02 vs controls), while treatment of either islets or recipient mice only, was associated with median graft survivals of 41.5 days and 14 days, respectively (as compared to 12.5 control animals). Donor-specific skin graft rechallenge in non-rejecting animals resulted in rejection of both skin and islets, but without accelerated rejection as compared to naive animals.

Taken together, our data indicate that TLR4 blockade leads to enhanced syngeneic marginal mass islet engraftment and indefinite allogeneic islet graft survival. TLR4 blockade is as critical on donor islets as it is on host immune cells. Mechanisms are likely to involve graft accommodation with concurrent inhibition of donor-specific immune memory.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Berney T, Giovannoni L, Lavallard V, Muller Y, Lacotte S, Morel P, Toso C, Shang L, Daubeuf B, Kosco-Vilbois M, Bosco D. Toll-Like Receptor 4 Blockade Enhances Islet Engraftment and Induces Indefinite Islet Allograft Survival [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/toll-like-receptor-4-blockade-enhances-islet-engraftment-and-induces-indefinite-islet-allograft-survival/. Accessed February 25, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.